康寧傑瑞製藥-B(09966.HK):KN046治療晚期PDAC的III期臨牀試驗完成首例患者給藥
格隆匯2月9日丨康寧傑瑞製藥-B(09966.HK)發佈公吿,KN046的III期臨牀試驗已成功完成首例患者給藥。KN046-303是一項多中心、隨機、雙盲、安慰劑對照的臨牀試驗,旨在對未接受系統性治療的不可切除局部晚期或轉移性PDAC患者進行試驗,用以評估 KN046聯合白蛋白紫杉醇及吉西他濱對比安慰劑聯合白蛋白紫杉醇及吉西他濱的療效及安全性。該試驗計劃入組408例受試者,主要終點為總生存期。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.